|
Daily Medical Update
Stable Angina
Sunday, May 10, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of the American College of Cardiology (2025) - Secondary analysis of randomized trial
Key Findings
- Higher dobutamine stress echocardiography ischemia scores predicted greater placebo-controlled improvement in angina symptom score after PCI (OR 1.23; 95% CrI 1.13-1.35; interaction probability >99.9%).
- Greater ischemia also predicted fewer daily angina episodes after PCI (OR 1.36; 95% CrI 1.24-1.49) plus better Seattle Angina Questionnaire angina frequency and quality-of-life scores.
📋 Practice Implication: Use demonstrable ischemia burden, not anatomy alone, when discussing PCI for symptom relief in stable angina patients who remain candidates for revascularization.
|
Critical pathways in cardiology (2025) - Systematic review and meta-analysis of randomized trials
Key Findings
- Across 28 randomized trials, PCI lowered myocardial infarction incidence versus medical management over 2.64 years of follow-up (OR 0.84; 95% CI 0.74-0.96; P = 0.01).
- PCI did not improve freedom from angina, stroke, all-cause mortality, or cardiovascular death versus medical therapy, and reductions in unplanned revascularization and major adverse cardiovascular events were not statistically significant.
📋 Practice Implication: Frame PCI as a selective strategy with possible myocardial infarction reduction rather than a routine path to better survival or broad symptom superiority over optimized medical therapy.
|
JAMA cardiology (2025) - Long-term follow-up of randomized clinical trial
Key Findings
- At 10.6 years of median follow-up, all-cause death was similar with initial CTA vs stress testing (14.3% vs 14.5%; HR 0.98; 95% CI 0.87-1.10).
- Cardiovascular mortality also did not differ significantly between testing strategies, while any abnormal CTA finding carried higher mortality risk than a normal CTA and only severe stress-test abnormalities were prognostically significant.
📋 Practice Implication: Choose the initial noninvasive test based on local expertise and patient factors, because long-term survival appears equivalent across functional and anatomic first-test strategies.
|
Lakartidningen (2025) - Guideline summary
Key Findings
- The 2024 ESC chronic coronary syndrome guidance recommends coronary CT angiography first-line for low-to-moderate probability disease vs functional imaging for moderate-to-high probability disease.
- The guideline update sets an LDL cholesterol reduction target below 1.4 mmol/L and recommends microcirculatory investigation when non-obstructive disease coexists with persistent angina.
📋 Practice Implication: Update stable angina pathways to pair pretest-probability-based imaging with stricter preventive targets and a lower threshold to investigate coronary microvascular dysfunction.
|
The Journal of international medical research (2025) - Meta-analysis
Key Findings
- Across 11 trials, PCSK9 inhibitor plus statin therapy significantly reversed coronary plaque versus control (p < 0.001).
- Combination therapy increased fibrous cap thickness and reduced LDL cholesterol and lipoprotein(a), although atheroma volume did not differ significantly from control.
📋 Practice Implication: Consider escalation beyond statins in high-risk stable angina patients with residual lipid-driven risk, especially when plaque modification is a treatment goal.
|
|
💡
Summary
Recent stable angina evidence sharpens patient selection more than it changes baseline strategy: ischemia burden on dobutamine stress echocardiography identified patients most likely to gain symptom and quality-of-life benefit from PCI, while pooled randomized data still showed little mortality or angina advantage for PCI over optimal medical therapy overall. Long-term diagnostic outcomes remained similar between initial stress testing and coronary CTA, and newer chronic coronary syndrome guidance emphasizes aggressive lipid lowering and microvascular evaluation alongside anatomy-based testing pathways.
|
|